{"id":"W2128542677","doi":"10.1056/nejmoa1103782","title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7688,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Vemurafenib; Medicine; Dacarbazine; Interim analysis; Internal medicine; Adverse effect; Melanoma; Oncology; Rash; Dabrafenib; Progression-free survival; Nausea; Clinical trial; Cancer research; Metastatic melanoma; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}